SCHEMBL7100378

SCHEMBL7100378

COc1ccc(N(F)S(=O)(=O)c2cc(F)c(F)c(F)c2F)cc1OP(=O)(O)O

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 6/20 0.42
ATM Q13315 1/20 0.38
HDAC6 Q9UBN7 9/20 0.37
INPPL1 O15357 3/20 0.36
HDAC2 Q92769 1/20 0.35
INPP5A Q14642 2/20 0.33
MAPT P10636 1/20 0.33
HDAC11 Q96DB2 2/20 0.33
KDM4E B2RXH2 2/20 0.33
HDAC3 O15379 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C19 P33261 1/20 0.33
INPP5B P32019 1/20 0.33
ALDH1A1 P00352 1/20 0.32
POLB P06746 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6375671 0.83 HDAC8 (0.43) HDAC8ATMHDAC6HDAC2KDM4E
SCHEMBL7099461 0.82 TUBB1 (0.45) HDAC8ATMHDAC6HDAC2KDM4E
SCHEMBL6087582 0.71 HDAC6 (0.38) HDAC8HDAC6HDAC2HDAC11HDAC3
SCHEMBL7100377 0.66 LMNA (0.50) MAPTALDH1A1
SCHEMBL22909519 0.66 TAS2R14 (0.48) HDAC8HDAC6HDAC2ALDH1A1
SCHEMBL29671306 0.66 TAS2R14 (0.48) HDAC8HDAC6HDAC2ALDH1A1
SCHEMBL28762088 0.65 HDAC8 (0.40) HDAC8ATMHDAC6HDAC2MAPT
SCHEMBL7534445 0.65 TSHR (0.62) ALDH1A1POLB
SCHEMBL28412637 0.64 INPPL1 (0.62) INPPL1INPP5AKDM4EINPP5BALDH1A1
SCHEMBL27528600 0.63 TUBB4A (0.47) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1090014-B1 ARYLSULFONANILIDE PHOSPHATES TULARIK INC (US) 2003-09-03 EP disclosed
US-6417176-B2 ANTICANCER AGENTS, PSORIASIS, RESTENOSIS, ATHEROSCLEROSIS TULARIK, INC. 2002-07-09 US disclosed
US-20010018430-A1 Arylsulfonanilide phosphates TULARIK, INC. 2001-08-30 US disclosed
EP-1090014-A1 ARYLSULFONANILIDE PHOSPHATES Tularik Inc. (US) 2001-04-11 EP disclosed
US-6211167-B1 ANTICHOLESTEROL, ANTIPROLIFERATIVE AND ANTILIPEMIC AGENTS; CANCER, PSORIASIS, ATHEROSCLEROSIS, INFECTION AND VASCULAR RESTENOSIS TREATMENT TULARIK INC. 2001-04-03 US disclosed
WO-1999067258-A1 ARYLSULFONANILIDE PHOSPHATES TULARIK INC. (US) 1999-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010018430-A1 Arylsulfonanilide phosphates PIK3CA, INPP5D, INPPL1 HDAC8 1023/4885ATM 1222/4885HDAC6 1986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.